Screening for Wilms' tumor in children with high-risk congenital syndromes: Considerations for an intervention trial

Medical and Pediatric Oncology

Volumn 27, Issue 5, 1996, Pages 415-421

  DeBaun, Michael R ^a   Brown, Martin ^a   Kessler, Larry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer screening; intervention trial; Wilms' tumor

Indexed keywords

ARTICLE; CANCER SCREENING; CHILD; CLINICAL TRIAL; CONGENITAL MALFORMATION; COST BENEFIT ANALYSIS; ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; NEPHROBLASTOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION;

CHILD; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INTERVENTION STUDIES; KIDNEY NEOPLASMS; MASS SCREENING; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SYNDROME; WILMS TUMOR;

EID: 0029816224     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199611)27:5<415::AID-MPO5>3.0.CO;2-P     Document Type: Article

References (38)

1. Miller RW, Fraumeni JF, Manning MD: Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital malformations. N Engl J Med 270:922-927, 1964.
2. Sotelo-Avila C, Gonzalez-Cruzi F, Fowler JW: Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potential. J Pediatr 96:47-50, 1980.
3. Neri G, Martin-Nevi ME, Katz BE, Optiz JM: The Perlman syndrome: Familial renal dysplasia with Wilms' tumor, fetal gigantism and multiple congenital abnormalities. Am J Med Genet 19:195-207, 1984.
4. Hersh JH, Cole TRP, Bloom AS, Bertolone SJ, Hughes HE: Risk of malignancy in Sotos syndrome. J Pediatr 120:572-574, 1992.
5. Montagne JP: Discussion at the 18th congress of the European Society of Pediatric Radiology, Oslo, May 20-23, 1981.
6. Andrews MW, Amparo EG: Wilms' tumor in a patient with Beckwith-Wiedemann syndrome: Onset detected with 3-month serial sonography. Am J Radiol 160:139-140, 1993.
7. Shah KJ: Beckwith-Wiedemann syndrome: Role of ultrasound in its management. Clin Radiol 34:313-319, 1983.
8. Wiedemann HR: Tumours and hemihypertrophy associated with Wiedemann Beckwith syndrome (letter). Eur J Pediatr 141:129, 1983.
9. Craft AW, Parker L, Stiller C, Cole M: Screening for Wilms' tumor in patients with anividia, Beckwith syndrome of hemihypertrophy. Med Pediatr Oncol 24:231-234, 1995.
10. Green DM, Breslow NE, Beckwith JB, Norkovl P: Screening of children with hemihypertrophy, aniridia and Beckwith-Wiedemann syndrome in patients with Wilms' tumor. Med Pediatr Oncol 21:188-192, 1993.
11. Connor RJ, Prorok PC, Weed DL: The case control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol 44:1215-1221, 1991.
12. Weiss NS: Control definition in case-control studies of the efficacy of screening and diagnostic testing. Am J Epidemiol 118:457-460, 1983.
13. Brown ML, Kessler LG: The use of gene tests to detect hereditary predisposition to cancer: Economic considerations. J Natl Cancer Inst (in press).
14. Prorok PC, Connor RJ: Screening for the early detection of cancer. Cancer Invest 4:225-238, 1986.
15. Prorok PC: Epidemiologic approach for cancer screening problems in design and analysis of trials. Am J Pediatr Hematol Oncol 14:117-128, 1992.
16. D'Angio GJ, Brewlow N, Beckwith JB, Evans A, Baum E, deLorimier A, Fernback D, Hrabovsky E, Jones B, Kelalis P, Othersen HB, Tefft M, Thomas PRM: Treatment of Wilms' tumor. Results of the third national Wilms' tumor study. Cancer 64:347-360, 1989.
17. The Wilms Tumor Study Committee: J Oncol 9:877-887, 1991.
18. Draper GJ, Birch JM, Bithell JF, et al: "Childhood Cancer in Britain. Studies on Medical and Population Subjects." London: HMSO, 1982 (No. 37).
19. Chamberlain J: Screening for neuroblastoma: A review of the evidence. J Med Screening 1:169-175, 1994.
20. Feuer EJ, Wun LM: DEVCAN: "Probability of DEVeloping CANcer software," Version 3.1. Rockville, MD: National Cancer Institute, 1994.
21. Butturini A, Gale RP, Verkinder PC, Adler-Brecher B, Bittio AP, Averback AD: Hematologic abnormalities in Fanconi anemia. International Fanconi Anemia Registry Study. Blood 84:1650, 1994.
22. Germain J, Passarge E: Blooms syndrome XII. Report from the Registry for 1987. Clin Genet 38:57-69, 1989.
23. Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia telangiectasia. N Engl J Med 325:1831-1866, 1991.
24. Hutchison GB, Shapiro S: Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 41:665-681, 1968.
25. Walter SD, Day NE: Estimation of the duration of pre-clinical disease state using screening data. Am J Epidemiol 118:865-886, 1983.
26. Koning HJ de, Ineveld BM van, Oortmarssen GJ van, Haes JHCJM de, Collette HJA, Hendriks JHCL, Maas PJ van der: Breast cancer screening and cost-effectiveness: Policy alternatives, quality of life considerations, and the possible impact of uncertain factors. Int J Cancer 49:531-537, 1991.
27. Tubiana M, Koscielny S: The natural history of breast cancer: Implications for a screening strategy. Int J Radiat Oncol Biol Phys 19:1117-1120, 1990.
28. Shackney SE, McCormack GW, Cuchural GJ: Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89:107-121, 1978.
29. Dwyer AJ, Prewitt JMS, Ecker JG, Plunkett J: Use of the hazard rate to schedule follow-up exams efficiently. Med Decis Making 3:229-244, 1983.
30. Russell LB: "Educated Guesses: Making Policy About Medical Screening Tests." Berkeley, CA: University of California Press, 1994.
31. Cella DF, Tulsky DS: Measuring quality of life today: Methodologic aspects. Oncology 4:29-38, 1990.
32. Drummond MF, Stoddart GL, Torrance GW: "Methods for Economic Evaluation of Health Care Programmes." New York: Oxford University Press, 1987.
33. Lesser JA, Zerbe RO: Discounting procedures for environmental (and other) projects. J Policy Anal Management 13:140-156, 1994.
34. U.S. Office of Management and Budget: "Revised Circular no. A-94." Washington, DC: U.S. Office of Management and Budget.
35. U. S. Congress. Office of Technology Assessment: "Cost Effectiveness of Colorectal Cancer Screening in Average-Risk Adults (OTA-BP-H-146)." Washington, DC: U.S. Government Printing Office, April 1995.
36. Brown ML, Fintor L: Cost-effectiveness of breast cancer screening: Preliminary results of a systematic review of the literature. Breast Cancer Res Treatment 25:113-118, 1993.
37. Fahs MC, Mandelblatt J, Schechter C, Muller C: Cost-effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117:520-527, 1992.
38. Brown ML: Sensitivity analysis in the cost-effectiveness of breast cancer screening. Cancer 69:1963-1967, 1992.